Differential effects of myopathy-associated caveolin-3 mutants on growth factor signaling.
Caveolin-3 is an important scaffold protein of cholesterol-rich caveolae. Mutations of caveolin-3 cause hereditary myopathies that comprise remarkably different pathologies. Growth factor signaling plays an important role in muscle physiology; it is influenced by caveolins and cholesterol-rich rafts and might thus be affected by caveolin-3 dysfunction. Prompted by the observation of a marked chronic peripheral neuropathy in a patient suffering from rippling muscle disease due to the R26Q caveolin-3 mutation and because TrkA is expressed by neuronal cells and skeletal muscle fibers, we performed a detailed comparative study on the effect of pathogenic caveolin-3 mutants on the signaling and trafficking of the TrkA nerve growth factor receptor and, for comparison, of the epidermal growth factor receptor. We found that the R26Q mutant slightly and the P28L strongly reduced nerve growth factor signaling in TrkA-transfected cells. Surface biotinylation experiments revealed that the R26Q caveolin-3 mutation markedly reduced the internalization of TrkA, whereas the P28L did not. Moreover, P28L expression led to increased, whereas R26Q expression decreased, epidermal growth factor signaling. Taken together, we found differential effects of the R26Q and P28L caveolin-3 mutants on growth factor signaling. Our findings are of clinical interest because they might help explain the remarkable differences in the degree of muscle lesions caused by caveolin-3 mutations and also the co-occurrence of peripheral neuropathy in the R26Q caveolinopathy case presented.
Brauers
Eva
E
Institute of Medical Microbiology, Medical Faculty, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.
Dreier
Agnes
A
Roos
Andreas
A
Wormland
Berthold
B
Weis
Joachim
J
Krüttgen
Alexander
A
D000328:Adult; D000818:Animals; D051244:Caveolin 3 / Q000235:genetics / Q000378:metabolism; D002460:Cell Line; D004815:Epidermal Growth Factor / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D009135:Muscular Diseases / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D020932:Nerve Growth Factor / Q000378:metabolism*; D051381:Rats; D020800:Receptor, Nerve Growth Factor / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*
D051244:Caveolin 3; D020800:Receptor, Nerve Growth Factor; D004815:Epidermal Growth Factor; D020932:Nerve Growth Factor; D066246:ErbB Receptors; D048049:Extracellular Signal-Regulated MAP Kinases
J Biol Chem. 2005 Apr 8;280(14):13483-6
15699039
J Biol Chem. 2002 May 17;277(20):17944-9
11884389
Annu Rev Neurosci. 1996;19:463-89
8833451
J Biol Chem. 1995 Aug 4;270(31):18285-94
7629148
Hum Mol Genet. 2000 Sep 22;9(15):2335-40
11001938
J Biol Chem. 2000 Dec 1;275(48):37846-52
10982788
J Neurosci. 2005 Nov 23;25(47):10930-40
16306406
Neuroscience. 2003;120(1):31-40
12849738
J Neuroimmunol. 2005 Aug;165(1-2):11-20
15925413
J Biol Chem. 1999 Jan 1;274(1):257-63
9867838
Int Anesthesiol Clin. 2006 Spring;44(2):21-76
16849956
Am J Pathol. 1996 Jun;148(6):1807-18
8669468
Exp Mol Med. 2003 Dec 31;35(6):538-44
14749532
Biochim Biophys Acta. 1993 Jun 5;1148(2):249-56
8389198
J Pharmacol Exp Ther. 2005 May;313(2):485-91
15608075
J Histochem Cytochem. 2003 Sep;51(9):1113-8
12923236
Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H392-401
17982011
Am J Physiol Cell Physiol. 2003 Nov;285(5):C1150-60
12839838
J Biol Chem. 1997 Nov 28;272(48):30429-38
9374534
Am J Pathol. 2003 Dec;163(6):2619-34
14633633
Dev Neurobiol. 2007 Aug;67(9):1183-203
17514710
Acta Neuropathol. 1998 Nov;96(5):495-501
9829813
J Biol Chem. 1993 Sep 5;268(25):19000-3
8395524
Nat Cell Biol. 2003 May;5(5):382-4
12724770
Dev Dyn. 2000 Jul;218(3):438-51
10878609
Hum Mol Genet. 1998 May;7(5):871-7
9536092
Neurology. 2004 Feb 24;62(4):538-43
14981167
Sci STKE. 2005 Jan 18;2005(267):pe1
15657262
Nature. 1984 May 31-Jun 6;309(5967):418-25
6328312
J Neurosci. 1999 Aug 1;19(15):6538-48
10414982
Neurology. 2001 Dec 26;57(12):2273-7
11756609
J Neurol Neurosurg Psychiatry. 2002 Jul;73(1):65-7
12082049
Brain Res. 1998 Sep 7;804(2):177-92
9841091
Oncogene. 2005 May 5;24(20):3309-18
15735700
FEBS Lett. 1996 Jan 2;378(1):108-12
8549793
Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9
11413487
Diabetes. 2009 Nov;58(11):2677-86
19675140
Mol Cell Neurosci. 2005 Mar;28(3):571-87
15737746
Sci Signal. 2009 Jul 28;2(81):ra38
19638615
Methods Mol Biol. 1999;116:51-60
10399145
Int J Dev Neurosci. 2000 Dec;18(8):869-85
11154856
J Cell Biol. 2007 Oct 22;179(2):341-56
17938246
Curr Opin Neurobiol. 2002 Oct;12(5):542-9
12367633
J Biol Chem. 2004 Aug 13;279(33):34614-23
15190056
Am J Med Genet. 2001 Apr 1;99(4):303-7
11251997
Mol Neurobiol. 2007 Apr;35(2):151-9
17917104
Biochem Biophys Res Commun. 2009 Sep 18;387(2):360-4
19607811
Neurosci Lett. 2001 Mar 30;301(2):107-10
11248434
Int J Cancer. 2009 Sep 15;125(6):1257-65
19499547
J Biol Chem. 1999 Sep 3;274(36):25632-41
10464299
Lab Invest. 2008 Mar;88(3):275-83
18253147
Cancer Res. 2007 Oct 15;67(20):9986-95
17942932
J Biol Chem. 1999 Oct 22;274(43):30636-43
10521449